We are live on ! Find out more
ROIV icon

Roivant Sciences

318 hedge funds and large institutions have $6.65B invested in Roivant Sciences in 2024 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 94 increasing their positions, 103 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 41

9% more funds holding

Funds holding: 293318 (+25)

1% more capital invested

Capital invested by funds: $6.57B → $6.65B (+$86.7M)

0.32% more ownership

Funds ownership: 76.97%77.28% (+0.32%)

0% more funds holding in top 10

Funds holding in top 10: 1717 (0)

9% less repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 103

14% less call options, than puts

Call options by funds: $9.58M | Put options by funds: $11.1M

Holders
318
Holders Change
+25
Holders Change %
+8.53%
% of All Funds
4.19%
Holding in Top 10
17
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.22%
New
69
Increased
94
Reduced
103
Closed
41
Calls
$9.58M
Puts
$11.1M
Net Calls
-$1.53M
Net Calls Change
+$14.2M
Name Holding Trade Value Shares
Change
Change in
Stake
QF
1
QVT Financial
New York
$778M
SIAU
2
SB Investment Advisers (UK)
United Kingdom
$734M -$45.8M -3,876,537 -6%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$583M +$1.85M +156,527 +0.3%
Viking Global Investors
4
Viking Global Investors
Connecticut
$566M -$74.4M -6,289,106 -12%
Vanguard Group
5
Vanguard Group
Pennsylvania
$522M +$28.4M +2,404,232 +6%
BlackRock
6
BlackRock
New York
$499M +$2.31M +195,472 +0.5%
Morgan Stanley
7
Morgan Stanley
New York
$409M +$58.4M +4,941,069 +17%
State Street
8
State Street
Massachusetts
$246M +$14.7M +1,240,463 +6%
RCMNY
9
Rubric Capital Management (New York)
New York
$237M -$28.4M -2,400,000 -11%
PSC
10
Patient Square Capital
California
$148M +$2.97M +251,535 +2%
TSC
11
Two Seas Capital
New York
$120M +$5.24M +442,914 +5%
Invesco
12
Invesco
Georgia
$113M +$37.4M +3,159,603 +50%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$92M +$316K +26,727 +0.3%
WP
14
Woodline Partners
California
$72.5M -$30.2M -2,554,528 -29%
TCIM
15
TOMS Capital Investment Management
New York
$69.6M +$22.1M +1,870,000 +47%
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$67.7M -$411K -34,752 -0.6%
UBS Group
17
UBS Group
Switzerland
$62.6M +$56.5M +4,779,042 +936%
DCM
18
DME Capital Management
New York
$62.4M -$437K -36,973 -0.7%
ACG
19
Anchorage Capital Group
New York
$57.2M
Norges Bank
20
Norges Bank
Norway
$52.4M +$557K +47,074 +1%
BCP
21
BlackBarn Capital Partners
New York
$48.8M +$1.48M +125,000 +3%
BBA
22
Baker Bros. Advisors
New York
$44.6M +$11.5M +969,057 +35%
Loomis, Sayles & Company
23
Loomis, Sayles & Company
Massachusetts
$43.4M -$2.85M -241,194 -6%
ACM
24
ADAR1 Capital Management
Texas
$41.5M +$5.71M +483,244 +16%
PCH
25
Polar Capital Holdings
United Kingdom
$41.4M

ROIV Hedge Fund Activity: Q4 2024 in Review

318 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q4 2024, worth a combined $6.65B — up 1.3% from $6.57B a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new ROIV positions and 41 closed out — a net gain of 28 holders — while 94 added to existing stakes and 103 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $58.4M. The largest seller was Viking Global Investors, cutting an estimated $74.4M.

  • 318 institutional investors held Roivant Sciences (ROIV) as of Q4 2024, up from 293 in Q3 2024.
  • Funds reported $6.65B of Roivant Sciences stock for Q4 2024, up 1.3% quarter-over-quarter.
  • 69 funds opened new Roivant Sciences positions in Q4 2024 and 41 closed out, a net change of +28 holders.
  • The largest Roivant Sciences buyer in Q4 2024 was Morgan Stanley, an estimated $58.4M added.
  • The largest Roivant Sciences seller in Q4 2024 was Viking Global Investors, an estimated $74.4M sold.

Based on aggregated 13F filings for Q4 2024.